HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Anemia

Subscribe to New Research on Anemia

Share|Follow on Twitter

A reduction in the number of circulating erythrocytes or in the quantity of hemoglobin.

Also Known As:

Anemias

Networked: 19058 relevant articles (1290 outcomes, 1930 trials/studies) for this Disease, Comments

Relationship Network

Disease Context: Research Results

Hemic and Lymphatic Diseases
- Hematologic Diseases: 1672
  - Anemia: 19058

Related Diseases

1.	Neoplasms (Cancer)
2.	Chronic Kidney Failure (Chronic Renal Failure)
3.	Thrombocytopenia (Thrombopenia)
4.	Kidney Diseases (Kidney Disease)
5.	Neutropenia

Experts

1.	Locatelli, Francesco: 20 articles (11/2012 - 07/2002)
2.	Ganz, Tomas: 19 articles (11/2012 - 07/2004)
3.	Coyne, Daniel W: 17 articles (05/2010 - 07/2002)
4.	Nemeth, Elizabeta: 15 articles (11/2012 - 02/2005)
5.	Semba, Richard D: 15 articles (07/2012 - 01/2002)
6.	Lang, Florian: 14 articles (02/2010 - 01/2006)
7.	Fishbane, Steven: 13 articles (11/2012 - 07/2005)
8.	Ferrucci, Luigi: 13 articles (09/2012 - 08/2003)
9.	Bennett, Charles L: 13 articles (03/2010 - 09/2002)
10.	Ludwig, Heinz: 12 articles (09/2012 - 06/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Anemia:

1.	Erythropoietin FDA Link 05/01/2001 - "The most promising results have been noted in the treatment of erythropoietin-resistant anemia. " 09/04/1991 - "[Erythropoietin is highly effective in renal anemia but should be prescribed with caution]." 02/01/2007 - "Recombinant human erythropoietin (rhEpo) has proven to be remarkably safe and effective for treatment of anemias, primarily those secondary to renal disease and malignancy. " 01/01/2006 - "The only proven effective prevention of RBV-induced anemia is the concomitant administration of erythropoietin. " 05/01/1997 - "Recombinant human erythropoietin (rHuEPO) is used extensively in anemic patients on dialysis and other patients and is regarded as very safe and effective in the management of anemia in these patients. " Order ALL the reference details at left...
2.	IronIBA 04/15/2011 - "Most anemias were asymptomatic and improved with iron/multivitamin supplementation and cessation of ZDV exposure. " 05/01/2004 - "The regimen with iron administered daily is still the best option for treating anemia. " 02/15/2003 - "The combination of IPT and iron supplementation was most effective in the treatment of mild anemia. " 09/01/2001 - "Paired analysis of 875 patients present in 1996 and 1998 showed that, although there was a marked increase in the use of IV iron, the improvement in anemia was modest, and there was evidence for increased iron accumulation. " 01/01/1995 - "However, therapy with EPO plus iron and adequate nutrition is likely to be proven effective for the relatively late anemia of stable prematures. " Order ALL the reference details at left...
3.	Hemoglobins (Hemoglobin)IBA 09/01/2007 - "Children who benefited the most from anthelmintic treatment in terms of increased hemoglobin concentrations were those who had anemia at baseline and those with highly positive microhematuria scores at baseline. " 07/01/1980 - "Anemia is the abnormality most likely to be encountered, and investigation of a marginal reduction in the hemoglobin level of an elderly patient may be rewarded with a specific diagnosis of a disease that can be effectively treated, at least for a time." 01/01/1996 - "In univariate analysis, factors associated with poor survival were stage IV (Ann Arbor staging system), anemia (hemoglobin level less than 10g/dl), bone marrow involvement, two or more extranodal sites, and failure in induction of complete remission (CR) in the entire course. " 05/01/1991 - "After operation, the anemia markedly improved while rHuEPO was administered, but the hemoglobin levels decreased rapidly when the administration was terminated. " 01/01/2002 - "In the majority of these studies, the long-term treatment of MM-associated anemia with rHuEPO-alpha induced a significant improvement of erythropoiesis, as shown by a stable increase of hemoglobin values (> or = 2g/dL) and reduction of transfusion requirements. " Order ALL the reference details at left...
4.	Epoetin Alfa (Epogen)FDA Link 04/01/1993 - "For most patients, therapy with Epoetin alfa reverses anemia and provides them with many benefits, including an improved quality of life. " 08/01/2003 - "Epoetin alfa has proven efficacy and safety in correcting anemia and improving QOL based on numerous clinical studies and over a decade of clinical practice. " 04/01/1992 - "Epoetin alfa therapy has been proven effective in treating anemia in dialysis patients; it increases the hematocrit (HCT) and improves the quality of life. " 02/01/2006 - "Early treatment with epoetin alfa to correct anemia improved QOL in a statistically significant and clinically meaningful way, and improvements were greater in patients with baseline Hb levels >10.5 g/dl." 06/01/2004 - "Once-weekly epoetin alfa therapy is safe and effective for treating anemia in patients with CKD not on dialysis, and is associated with significant improvements in functional status and quality of life." Order ALL the reference details at left...
5.	darbepoetin alfa (Aranesp)FDA Link 07/01/2009 - "With several-fold more patient-years and a placebo arm, TREAT will provide a robust estimate of the safety and efficacy of darbepoetin alfa and generate prospective data regarding the risks of major cardiovascular and renal events in a contemporarily managed cohort of patients with type 2 diabetes, CKD, and anemia." 06/01/2008 - "Darbepoetin alfa is an erythropoiesis-stimulating agent that has been shown to be effective in treating anemia in patients with CKD (but not on dialysis) when administered using extended-dosing regimens. " 09/01/2006 - "The objective of this study was to determine if darbepoetin alfa administered at a reduced dosing frequency relative to the prior rHuEpo regimen is an effective and safe alternative for treating renal anemia in patients undergoing dialysis. " 01/01/2005 - "Darbepoetin alfa is generally well tolerated, and clinical trials of 20-52 weeks' duration have demonstrated the efficacy of subcutaneous and intravenous administration at 1- or 2-week intervals in the initial treatment of anemia associated with CKD both in dialysis patients and in patients not yet on dialysis. " 07/01/2003 - "Furthermore, an improvement in health-related quality of life has been observed in association with anemia correction using darbepoetin alfa therapy in these patients. " Order ALL the reference details at left...
6.	MicronutrientsIBA 07/01/2002 - "Although not proven effective in this study, micronutrient supplementation should be prospectively assessed in HIV-infected infants as a means of preventing anemia." 06/01/2010 - "A daily dose of "Sprinkles" (SuppleForte, Heinz, Canada), a micronutrient home supplementation, was proven effective for the treatment of anemia worldwide. " 12/01/2005 - "An integrated community approach including mass deworming, health education, and multi-micronutrient supplementation was very effective in reducing anemia in Cambodian schoolchildren and should be adopted on a larger scale." 05/01/2012 - "Although the efficacy of micronutrient powders [MNPs; eg, Sprinkles MNP (Sprinkles Global Health Initiative)] in the reduction of anemia has been established, the effectiveness of these powders in real-world programs has seldom been assessed. " 01/01/2010 - "The three supplements IS, ISF and MMS increased Hb more than the FCF; the supplements that contained micronutrients (IFS and MMS) were more effective for reducing the prevalence of anemia. " Order ALL the reference details at left...
7.	HematinicsIBA 01/01/2010 - "The mainstay of treatment of anemia secondary to CKD has become erythropoiesis-stimulating agents (ESAs). " 01/01/2009 - "In these patients, erythropoiesis-stimulating agents (ESAs) are effective in managing anemia but there is an increased risk for thrombovascular events. " 06/01/2008 - "Several clinical trials have established the safety and efficacy of erythropoiesis-stimulating agents in correcting anemia in patients with HF. " 12/01/2012 - "Erythropoiesis-stimulating agents (ESA) are now central to the treatment of renal anemia and are associated with improved clinical outcomes. " 01/01/2012 - "As correction of anemia is associated with improved cardiac and renal function and quality of life, erythropoiesis-stimulating agents (ESAs) are standard therapy for anemia in CKD patients. " Order ALL the reference details at left...
8.	Recombinant ErythropoietinIBA 04/01/1992 - "Human recombinant erythropoietin constitutes a remarkable improvement in the treatment of uraemic anemia. " 10/08/1988 - "Human recombinant erythropoietin (r-huEPO) is very effective in the treatment of anemia of hemodialyzed patients. " 06/01/1999 - "Our case report shows that recombinant erythropoietin gives good results in treatment of anemia: correction of anemia, improvement of general status and there is no need for frequent transfusions and thus there are less complications." 09/01/1995 - "Such strategies include collection and banking of autologous placental blood, administration of recombinant erythropoietin, innovations in blood banking practices, and improved definitions of the markers of anemia with more rigorous transfusion guidelines. " 03/01/2003 - "Human recombinant erythropoietin is the main treatment for anemia in renal patients. " Order ALL the reference details at left...
9.	OxygenIBA 05/01/1996 - "This effect may be mediated via an improved oxygen supply to the endothelial cells due to the amelioration of anemia by rHuEPO." 03/01/2012 - "As central venous oxygen saturation (ScvO₂) may reflect imbalances in DO₂ and consumption (VO₂) the aim of this study was to investigate the value of ScvO₂ as an indicator of oxygen balance in isovolemic anemia. " 01/01/2012 - "Studies have generally shown that transfusion of red blood cells fails to increase oxygen uptake unless oxygen uptake/oxygen delivery dependency exists (e.g., severe anemia or strenuous exercise). " 09/01/2011 - "The benefit of high arterial oxygen partial pressure has significant potential clinical implications for the acute treatment of anemia and results of transfusion trials." 04/01/2011 - "The objective of this study was to determine systemic and microvascular effects of using a perfluorocarbon-based oxygen carrier (PFCOC) to maintain perfusion and oxygenation during extreme anemia. " Order ALL the reference details at left...
10.	Ribavirin (Virazole)FDA LinkGeneric 08/01/2012 - "ITPA rs1127354 major type leads to significantly greater ribavirin-induced anemia than ITPA rs1127354 minor type between days 0 and 84. " 07/01/2005 - "Unless ribavirin can be shown to be effective against SARS-coronavirus, the risk of anemia posed by this drug argues against its use in SARS patients." 08/01/2012 - "Following these studies, ITPA gene variants were reported to affect ribavirin-induced anemia and therapeutic outcomes of CHC patients. " 10/01/2010 - "ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients." 11/01/2004 - "This study was conducted to identify the factors contributing to ribavirin-induced anemia. " Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 07/01/2005 - "We conclude that darbepoetin alpha is a highly effective and well-tolerated drug in the treatment of chemotherapy-associated anemia. " 04/01/2004 - "In patients who achieve complete remission after chemotherapy, anemia usually normalizes. " 07/01/2006 - "Background: Patients receiving chemotherapy often experience chemotherapy-induced anemia, which contributes to a significant reduction in their quality of life. " 11/01/2002 - "Clinical data suggest that even a mild-to-moderate chemotherapy-induced anemia results in a significant reduction in a patient's energy level and QOL. " 02/01/1999 - "rHuEPO treatment (150 IU/kg/d 3 times a week) is effective and safe in children with chemotherapy-induced anemia. " Order ALL the reference details at left...
2.	Renal Dialysis (Hemodialysis) 04/01/2007 - "This clinical study showed that Espogen has proven effective and safe for treatment of anemia in hemodialysis patients. " 02/01/1989 - "It is concluded that r-huEPO is very effective in treating the anemia of patients maintained on hemodialysis. " 05/01/1997 - "Our study suggests that improvement of anemia in patients on long-term hemodialysis by administration of EPO is associated with an improvement in hearing capacity in a significant number of patients. " 02/01/1993 - "Anemia contributes to significant debilitation in hemodialysis patients and, when reversed with epoetin therapy, results in significantly improved muscle function and endurance." 06/01/2009 - "LOH is a well tolerated hemodialysis option, associated with improved URR and better control of anemia." Order ALL the reference details at left...
3.	Blood Transfusion (Blood Transfusions) 04/01/1999 - "Much of the increase in the patient's Hct vanishes at higher blood losses, and this therapy is most effective with blood loss of <4000 mL. EPO therapy alone may be most effectively used in patients with mild anemia who are undergoing routine surgical procedures that commonly require blood transfusion." 09/01/2005 - "Corticosteroid therapy and rinsed blood transfusion were very effective for anemia. " 03/01/1990 - "If proven effective in treating anemia in premature babies, r-HuEPO will be responsible for a major reduction in the use of blood transfusions in clinical neonatology. " 12/01/1996 - "A good outcome (neither recurrence of anemia nor blood transfusion requirements) was observed in 12 patients. " 10/01/1995 - "rHuEpo: (1) is effective and safe treatment for anemia in hds patients, sufficient to abolish blood transfusion requirements; (2) produces significant improvements in quality of life; and (3) allows for 50% costs reduction." Order ALL the reference details at left...
4.	Splenectomy 01/01/1987 - "Unique features of this case include the use of PE to avoid splenectomy, the complete and permanent clearance of detectable antibody following PE, and the rapid correction of anemia by infusing packed erythrocytes during the procedure. " 04/01/1983 - "Splenectomy induced marked improvement of anemia." 01/01/1987 - "The benefit of splenectomy for treatment of splenic hyperfunction depends on the stimulus to hyperfunction and may not be beneficial for patients with refractory autoimmune anemias." 01/01/1986 - "Splenectomy may be beneficial in anemias with erythrocyte rigidification if clinical condition so requires (repeated transfusions, aplastic and hemolytic crises). " 05/01/1985 - "For conditions other than congenital spherocytosis, in which splenectomy is uniformly of value, a decision to remove the spleen should be based on severity of the hemolytic process, failure to respond to other therapies, and the potential for achieving significant improvement in anemia and other associated cytopenias." Order ALL the reference details at left...
5.	Continuous Ambulatory Peritoneal Dialysis (CAPD) 07/01/1989 - "In conclusion, CAPD was known to be not always effective for the increment of Hb and Ht, while r-HuEPO was very effective for the improvement of severe anemia in CAPD patients which enabls them to lead better social life for them." 01/01/1994 - "Administration of relatively high doses of r-HuEPO to CAPD patients once a week or once every 2 weeks is safe and potentially an effective regimen for the correction of renal anemia." 10/01/1997 - "once a week is effective for children with anemia on CAPD but is insufficient for children on HD." 01/01/1993 - "Subcutaneous rHuEPO is effective in reversing anemia in HD and CAPD patients, but it takes longer to correct anemia in HD with the same initial SC rHuEPO low dose. " 01/01/1992 - "Conclusion: Subcutaneous rHuEPO is effective in correcting anemia in CAPD patients. " Order ALL the reference details at left...

blog comments powered by Disqus

TREATMENT OPTIONS
for Anemia,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 1290 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$24.95 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$490.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>